Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Pollock

Showing results (81-90 of 162) with videos related to

Pageof 17
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|January 8, 2008
Pure red cell aplasia induced by erythropoiesis-stimulating agentsCarol Pollock, David Wayne Johnson, Walter H Hörl, et al.
Intensive Care Medicine|May 1, 2015
Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trialGordon S Doig, Fiona Simpson, Rinaldo Bellomo, et al.
Frontiers in Pharmacology|March 25, 2022
Prior Cardiovascular Treatments-A Key Characteristic in Determining Medication Adherence After an Acute Myocardial InfarctionAnna Campain, Carinna Hockham, Louisa Sukkar, et al.
Surgery|November 11, 2018
Treatment strategy of end stage renal disease-related hyperparathyroidism before, during, and after the era of calcimimeticsWillemijn Y van der Plas, Anton F Engelsman, Marille Umakanthan, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 14, 2023
Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classificationCarol Pollock, Juan Jose Garcia Sanchez, Juan-Jesus Carrero, et al.
European Journal of Heart Failure|January 23, 2025
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trialsSafia Chatur, Muthiah Vaduganathan, Robert A Fletcher, et al.
Nature Reviews. Nephrology|April 4, 2024
A new era in the science and care of kidney diseasesCarmine Zoccali, Francesca Mallamaci, Liz Lightstone, et al.
Diabetes, Obesity & Metabolism|January 19, 2023
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trialAkihiko Koshino, Megumi Oshima, Clare Arnott, et al.
Clinical Kidney Journal|November 3, 2022
Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohortCarol Pollock, Glen James, Juan Jose Garcia Sanchez, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 19, 2025
Characteristics and cardio-renal outcomes in CKD patients receiving guideline-directed therapy: insights from DISCOVER CKDRoberto Pecoits-Filho, Eiichiro Kanda, Naoki Kashihara, et al.
Pageof 17

Showing results (81-90 of 162) with videos related to

Sort By:
Pageof 17
Clinical Journal of the American Society of Nephrology : CJASN|January 8, 2008
Pure red cell aplasia induced by erythropoiesis-stimulating agentsCarol Pollock, David Wayne Johnson, Walter H Hörl, et al.
Intensive Care Medicine|May 1, 2015
Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trialGordon S Doig, Fiona Simpson, Rinaldo Bellomo, et al.
Frontiers in Pharmacology|March 25, 2022
Prior Cardiovascular Treatments-A Key Characteristic in Determining Medication Adherence After an Acute Myocardial InfarctionAnna Campain, Carinna Hockham, Louisa Sukkar, et al.
Surgery|November 11, 2018
Treatment strategy of end stage renal disease-related hyperparathyroidism before, during, and after the era of calcimimeticsWillemijn Y van der Plas, Anton F Engelsman, Marille Umakanthan, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 14, 2023
Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classificationCarol Pollock, Juan Jose Garcia Sanchez, Juan-Jesus Carrero, et al.
European Journal of Heart Failure|January 23, 2025
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trialsSafia Chatur, Muthiah Vaduganathan, Robert A Fletcher, et al.
Nature Reviews. Nephrology|April 4, 2024
A new era in the science and care of kidney diseasesCarmine Zoccali, Francesca Mallamaci, Liz Lightstone, et al.
Diabetes, Obesity & Metabolism|January 19, 2023
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trialAkihiko Koshino, Megumi Oshima, Clare Arnott, et al.
Clinical Kidney Journal|November 3, 2022
Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohortCarol Pollock, Glen James, Juan Jose Garcia Sanchez, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 19, 2025
Characteristics and cardio-renal outcomes in CKD patients receiving guideline-directed therapy: insights from DISCOVER CKDRoberto Pecoits-Filho, Eiichiro Kanda, Naoki Kashihara, et al.
Pageof 17